Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 529.21 Thousand CAD | -12.51% |
| 2022 | 604.89 Thousand CAD | 616.04% |
| 2021 | 84.47 Thousand CAD | -92.68% |
| 2020 | 1.15 Million CAD | 71.27% |
| 2019 | 673.85 Thousand CAD | 114.44% |
| 2018 | 314.23 Thousand CAD | -21.85% |
| 2017 | 402.08 Thousand CAD | 12.52% |
| 2016 | 357.34 Thousand CAD | 90.97% |
| 2015 | 187.12 Thousand CAD | 18.94% |
| 2014 | 157.32 Thousand CAD | -56.82% |
| 2013 | 364.3 Thousand CAD | -72.83% |
| 2012 | 1.34 Million CAD | 6.68% |
| 2011 | 1.25 Million CAD | 12.86% |
| 2010 | 1.11 Million CAD | 1881.27% |
| 2009 | 56.21 Thousand CAD | -2.95% |
| 2008 | 57.92 Thousand CAD | -22.01% |
| 2007 | 74.26 Thousand CAD | 24.81% |
| 2006 | 59.5 Thousand CAD | 99.24% |
| 2005 | 29.86 Thousand CAD | -2.22% |
| 2004 | 30.54 Thousand CAD | -70.51% |
| 2003 | 103.56 Thousand CAD | 1833.89% |
| 2002 | 5355.00 CAD | 32.78% |
| 2001 | 4033.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 341.17 Thousand CAD | -40.92% |
| 2024 Q1 | 577.47 Thousand CAD | 9.12% |
| 2023 Q2 | 356.43 Thousand CAD | -12.74% |
| 2023 FY | 529.21 Thousand CAD | -12.51% |
| 2023 Q4 | 529.21 Thousand CAD | -18.14% |
| 2023 Q3 | 646.49 Thousand CAD | 81.38% |
| 2023 Q1 | 408.48 Thousand CAD | -32.47% |
| 2022 Q2 | 127.04 Thousand CAD | 91.1% |
| 2022 FY | 604.89 Thousand CAD | 616.04% |
| 2022 Q4 | 604.89 Thousand CAD | 60.44% |
| 2022 Q3 | 377.01 Thousand CAD | 196.77% |
| 2022 Q1 | 66.47 Thousand CAD | -21.31% |
| 2021 Q2 | 183.83 Thousand CAD | -13.49% |
| 2021 Q1 | 212.49 Thousand CAD | -81.59% |
| 2021 Q3 | 197.87 Thousand CAD | 7.63% |
| 2021 FY | 84.47 Thousand CAD | -92.68% |
| 2021 Q4 | 84.47 Thousand CAD | -57.31% |
| 2020 Q1 | 1.25 Million CAD | 85.63% |
| 2020 Q2 | 1.37 Million CAD | 9.84% |
| 2020 FY | 1.15 Million CAD | 71.27% |
| 2020 Q3 | 1.26 Million CAD | -7.66% |
| 2020 Q4 | 1.15 Million CAD | -9.03% |
| 2019 Q1 | 325.3 Thousand CAD | 3.52% |
| 2019 Q2 | 492.09 Thousand CAD | 51.27% |
| 2019 Q3 | 598.54 Thousand CAD | 21.63% |
| 2019 Q4 | 673.85 Thousand CAD | 12.58% |
| 2019 FY | 673.85 Thousand CAD | 114.44% |
| 2018 Q4 | 314.23 Thousand CAD | 53.45% |
| 2018 Q3 | 204.77 Thousand CAD | 2.51% |
| 2018 Q2 | 199.76 Thousand CAD | -34.99% |
| 2018 Q1 | 307.3 Thousand CAD | -23.57% |
| 2018 FY | 314.23 Thousand CAD | -21.85% |
| 2017 Q4 | 402.08 Thousand CAD | 88.55% |
| 2017 FY | 402.08 Thousand CAD | 12.52% |
| 2017 Q3 | 213.25 Thousand CAD | -67.24% |
| 2017 Q2 | 650.96 Thousand CAD | 90.58% |
| 2017 Q1 | 341.57 Thousand CAD | -4.41% |
| 2016 FY | 357.34 Thousand CAD | 90.97% |
| 2016 Q3 | 353.69 Thousand CAD | 12.51% |
| 2016 Q2 | 314.35 Thousand CAD | -28.07% |
| 2016 Q1 | 437.03 Thousand CAD | 77.49% |
| 2016 Q4 | 357.34 Thousand CAD | 1.03% |
| 2015 Q4 | 246.23 Thousand CAD | 1541.86% |
| 2015 Q3 | 14.99 Thousand CAD | -91.99% |
| 2015 Q1 | 50.42 Thousand CAD | 0.0% |
| 2015 Q2 | 187.12 Thousand CAD | 271.09% |
| 2015 FY | 187.12 Thousand CAD | 18.94% |
| 2014 Q2 | 157.32 Thousand CAD | -10.54% |
| 2014 Q4 | 50.42 Thousand CAD | -42.02% |
| 2014 Q1 | 175.86 Thousand CAD | -21.45% |
| 2014 FY | 157.32 Thousand CAD | -56.82% |
| 2014 Q3 | 86.97 Thousand CAD | -44.71% |
| 2013 FY | 364.3 Thousand CAD | -72.83% |
| 2013 Q4 | 223.89 Thousand CAD | -6.86% |
| 2013 Q3 | 240.38 Thousand CAD | -34.02% |
| 2013 Q2 | 364.3 Thousand CAD | -4.9% |
| 2013 Q1 | 383.05 Thousand CAD | 9.79% |
| 2012 Q3 | 315.01 Thousand CAD | -76.51% |
| 2012 Q1 | 1.33 Million CAD | -5.75% |
| 2012 Q2 | 1.34 Million CAD | 0.18% |
| 2012 Q4 | 348.9 Thousand CAD | 10.76% |
| 2012 FY | 1.34 Million CAD | 6.68% |
| 2011 FY | 1.25 Million CAD | 12.86% |
| 2011 Q4 | 1.42 Million CAD | 2.49% |
| 2011 Q3 | 1.38 Million CAD | 10.23% |
| 2011 Q1 | 1.09 Million CAD | 4.8% |
| 2011 Q2 | 1.25 Million CAD | 14.97% |
| 2010 Q3 | 983 Thousand CAD | -11.74% |
| 2010 Q4 | 1.04 Million CAD | 6.13% |
| 2010 Q1 | 110.83 Thousand CAD | -45.09% |
| 2010 FY | 1.11 Million CAD | 1881.27% |
| 2010 Q2 | 1.11 Million CAD | 904.92% |
| 2009 Q1 | 37.21 Thousand CAD | -46.49% |
| 2009 FY | 56.21 Thousand CAD | -2.95% |
| 2009 Q2 | 56.21 Thousand CAD | 51.06% |
| 2009 Q4 | 201.84 Thousand CAD | 0.0% |
| 2008 Q4 | 69.54 Thousand CAD | 31.92% |
| 2008 Q1 | 45.84 Thousand CAD | 16.21% |
| 2008 Q3 | 52.71 Thousand CAD | -8.98% |
| 2008 FY | 57.92 Thousand CAD | -22.01% |
| 2008 Q2 | 57.92 Thousand CAD | 26.34% |
| 2007 Q4 | 39.45 Thousand CAD | -27.99% |
| 2007 Q1 | 221.35 Thousand CAD | 68.05% |
| 2007 Q2 | 74.26 Thousand CAD | -66.45% |
| 2007 Q3 | 54.78 Thousand CAD | -26.23% |
| 2007 FY | 74.26 Thousand CAD | 24.81% |
| 2006 Q3 | 74.11 Thousand CAD | 24.56% |
| 2006 Q4 | 131.72 Thousand CAD | 77.72% |
| 2006 Q2 | 59.5 Thousand CAD | 17.25% |
| 2006 Q1 | 50.74 Thousand CAD | 36.95% |
| 2006 FY | 59.5 Thousand CAD | 99.24% |
| 2005 Q2 | 29.86 Thousand CAD | 29.88% |
| 2005 Q3 | 21.24 Thousand CAD | -28.86% |
| 2005 FY | 29.86 Thousand CAD | -2.22% |
| 2005 Q4 | 37.05 Thousand CAD | 74.41% |
| 2005 Q1 | 22.99 Thousand CAD | -52.97% |
| 2004 Q1 | 5304.00 CAD | 16475.0% |
| 2004 FY | 30.54 Thousand CAD | -70.51% |
| 2004 Q3 | 27.72 Thousand CAD | -9.22% |
| 2004 Q4 | 48.89 Thousand CAD | 76.37% |
| 2004 Q2 | 30.54 Thousand CAD | 475.83% |
| 2003 Q3 | 108.68 Thousand CAD | 4.94% |
| 2003 Q2 | 103.56 Thousand CAD | 0.0% |
| 2003 FY | 103.56 Thousand CAD | 1833.89% |
| 2003 Q4 | 32.00 CAD | -99.97% |
| 2003 Q1 | - CAD | 0.0% |
| 2002 FY | 5355.00 CAD | 32.78% |
| 2002 Q3 | 2500.00 CAD | 0.0% |
| 2002 Q4 | - CAD | -100.0% |
| 2001 FY | 4033.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 85.332% |
| Arrayit Corporation | 7.49 Million USD | 92.941% |
| Atlantic International Corp. | 3.82 Million USD | 86.177% |
| Biocept, Inc. | 22.01 Million USD | 97.596% |
| Bioqual, Inc. | 18.93 Million USD | 97.206% |
| CardioGenics Holdings Inc | 1.79 Million USD | 70.516% |
| DermTech, Inc. | 64.75 Million USD | 99.183% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.928% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 95.727% |
| iMD Companies, Inc. | 1.67 Million USD | 68.39% |
| IDenta Corp. | 1.01 Million USD | 47.766% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 98.12% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -77.622% |
| InVitro International | 78.99 Thousand USD | -569.981% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 97.318% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -309.304% |
| Medical Imaging Corp. | 9.51 Million USD | 94.439% |
| NovelStem International Corp. | 4.2 Million USD | 87.418% |
| Optigenex Inc. | 9.57 Million USD | 94.47% |
| PharmChem, Inc. | 558.64 Thousand USD | 5.268% |
| Proteome Sciences plc | 18.48 Million USD | 97.138% |
| Response Genetics, Inc | 15.86 Million USD | 96.665% |
| Rennova Health, Inc. | 49.66 Million USD | 98.934% |
| RushNet, Inc. | 6.23 Million USD | 91.518% |
| ScreenPro Security Inc. | 1.6 Million USD | 66.936% |
| Stella Diagnostics Inc. | 18 Million USD | 97.061% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 93.549% |
| Todos Medical Ltd. | 50.15 Million USD | 98.945% |